MyAlcon Professional Logo
MyAlcon for Consumer

A new path forward

 

focused on rapid activation of the natural tear mechanism1

A new path forward

focused on rapid activation of the natural tear mechanism1

Dry eye disease is driven by natural tear deficiency, whether due to decreased tear production or increased tear evaporation2,3
 

Despite availability of many treatment options, prescribers and patients report limitations of dry eye medications4-10

 
 
Top priorities for dry eye prescribers11,12
 
Alt text
Alt text

TIME TO ONSET

Alt text
Alt text

TREATMENT EFFECTIVENESS FOR SYMPTOMS OF DRY EYE

 
Challenges with current treatment options
 
 
Alt text
Alt text

Onset of results for some established dry eye disease treatments may take up to 
3-6 months4,13

Alt text
Alt text

Among surveyed dry eye patients, only 13% of patients felt their dry eye was well-managed14*

TRYPTYR: a first-in-class neuromodulator eye drop that stimulates corneal sensory nerves to rapidly increase natural tear production1,4-7

*Based on an online survey conducted by ChronicDryEye.net from February to April 2021 among 415 respondents who reported being diagnosed with chronic dry eye. 44% reported a severe level of chronic dry eye (ie, levels 3 and 4).14

Go beyond the surface

EXPLORE THE SCIENCE STAY INFORMED

Go beyond the surface

EXPLORE THE SCIENCE STAY INFORMED

  

REFERENCES

 

  1. TRYPTYR. Prescribing Information. Alcon, Inc., 2025.
  2. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438-510.
  3. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276-283.
  4. Restasis. Prescribing Information. AbbVie; 2024.
  5. Xiidra. Prescribing Information. Bausch & Lomb; 2023.
  6. Tyrvaya. Prescribing Information. Oyster Point Pharma, Inc., 2024.
  7. Miebo. Prescribing Information. Bausch & Lomb; 2023.
  8. Cook N, Mullins A, Gautam R, et al. Evaluating patient experiences in dry eye disease through social media listening research. Ophthalmol Ther. 2019;8:407-420.
  9. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007;114(1):76-79.
  10. Mbagwu M, LaPrise A. Characterization of discontinuation and switching patterns of dry eye disease medications using linked EHR registry and claims data. Paper presented at: American Society for Cataract and Refractive Surgery (ASCRS) Annual Meeting; April 5-8 2024; Boston, MA.
  11. White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. Physician satisfaction with anti-inflammatory topical medications for the treatment of dry eye disease. Clin Ophthalmol. 2020;14:931-938.
  12. White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. Treatment satisfaction among patients using anti-inflammatory topical medications for dry eye disease. Clin Ophthalmol. 2020;14:875-883.
  13. Hovanesian JA, Nichols KK, Jackson M, et al. Real-world experience with lifitegrast ophthalmic solution (Xiidra®) in the US and Canada: retrospective study of patient characteristics, treatment patterns, and clinical effectiveness in 600 patients with dry eye disease. Clin Ophthalmol. 2021;15:1041-1054.
  14. Morse H, Henneberger S, Reed J, et al. 2021 in American survey findings: living with chronic dry eye. ChronicDryEye. Accessed June 3, 2025. https://chronicdryeye.net/infographic/in-america-findings

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.

INDICATIONS AND USAGE

TRYPTYR (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Use with Contact Lenses: TRYPTYR should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration.

 

Adverse Reactions 

In clinical trials, the most common adverse reaction was instillation site pain (50%).

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

 

Please click here for the TRYPTYR Full Prescribing Information.